CNS Response Inc. has developed a data analysis capability that, when paired with a non-invasive EEG, analyzes a patient’s brain waves and compares those results to a patient outcome database, generating an rEEG report that allows psychiatrists to create personalized medication regimens for the patient.

According to the company, depression costs U.S. employers $83 billion annually; more than half of these costs are associated with treatment-resistant depression. Individuals with treatment-resistant depression cost $8,500 more per year than patients with ordinary depression. Through various studies, rEEG is the first objective, physiology-based, personalized medical technologies proven to efficiently and consistently enable psychiatrists to determine the right treatment for patients.

CNS Response today announced that Charles DeBattista, D.M.H, M.D., will present the results of a recent landmark study of rEEG at the U.S. Psychiatric and Mental Health Congress. The study proved rEEG effective at predicting medication response approximately 65 percent of the time.

“Psychiatry has lacked useful laboratory tests to select medications for treatment-resistant depressed patients. While needing further study, this trial is one of the larger ones to demonstrate that there may be a role for technology that assists physicians in selecting better treatment options for their patients,” Dr. Charles DeBattista, an award-winning doctor at Stanford University Medical Center, who helped lead the study on rEEG, stated in the press release.

The 12-week showed that rEEG significantly outperformed the control group STAR*D treatment algorithm; the difference between rEEG and the control group was 50 and 100 percent for the study’s two primary endpoints. According to the press release, the difference between a new treatment and a control group is about 10 percent in antidepressant studies.

“These outcomes are consistent with previous rEEG studies, which included three prospective, controlled trials and eight case series, but the robustness and statistical significance of these results exceeded our expectations,” said CNS Response president and Chief Medical Officer Daniel Hoffman, M.D.

George Carpenter, CEO of CNS Response, said the results hint at the future of depression treatment.

“This is the promise of personalized medicine, tailoring therapies to the unique medication response profile of each individual patient,” Carpenter stated. “Those suffering from the most resistant forms of depression will now have an effective treatment option, and doctors will no longer have to play an extended and costly guessing game to see what works best.”